A phase II study of laquinimod in Crohn's disease

Gut

Volumn 64, Issue 8, 2015, Pages 1227-1235

  D'Haens, Geert ^a   Sandborn, William J ^a   Colombel, Jean Frederic ^b,c   Rutgeerts, Paul ^d   Brown, Kurt ^e   Barkay, Hadas ^e   Sakov, Anat ^e   Haviv, Asi ^e,f   Feagan, Brian G ^g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e TEVA PHARMACEUTICALS   (Israel)

^f Chiasma   (Israel)

^g ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA AMYLASE PANCREAS ISOENZYME; LAQUINIMOD; PLACEBO; ANTIINFLAMMATORY AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; REMISSION; SEQUENTIAL ANALYSIS; TACHYCARDIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; ADOLESCENT; CLINICAL TRIAL; DOSE RESPONSE; INDUCTION CHEMOTHERAPY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; QUINOLONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940121888     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307118     Document Type: Article

References (30)

1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9.
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006;12:6102-8.
3. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002;16:1603-9.
4. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907-13.
5. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006;131:719-28.
6. Das KM. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine. Postgrad Med 1983;74:141-8, 150-1.
7. Frank MS, Brandt LJ, Bernstein LH. Pharmacotherapy of inflammatory bowel disease. Part 2. Metronidazole. Postgrad Med 1983;74:155-7, 160.
8. Pineton De Chambrun GP, Torres J, Darfeuille-Michaud A, et al. The role of anti (myco) bacterial interventions in the management of IBD: is there evidence at all? Dig Dis 2012;30:358-67.
9. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:590-9.
10. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010;(6): CD000545.
11. Girardin M, Manz M, Manser C, et al. First-line therapies in inflammatory bowel disease. Digestion 2012;86(Suppl 1):6-10.
12. Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012;18:4823-54.
13. Buchner AM, Blonski W, Lichtenstein GR. Update on the management of Crohn's disease. Curr Gastroenterol Rep 2011;13:465-74.
14. Katz S. "Mind the Gap": an unmet need for new therapy in IBD. J Clin Gastroenterol 2007;41:799-809.
15. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-97.
16. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-97.
17. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002;16:51-60.
18. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390-407.
19. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94.
20. Targan SR, Hanauer SB, Van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
21. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
22. Rutgeerts P, D'Haens G, Targan SR, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
23. Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci 2011;306:173-9.
24. Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004;156:3-9.
25. D'Haens GR, Sandborn W, Rutgeerts P, et al. Pharmacokinetics of laquinimod in patients with active moderate to severe Crohn's disease. Accepted for presentation at ECCO 2014. 21 February 2014.
26. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9.
27. Gurevich M, Gritzman T, Orbach R, et al. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in vitro high-throughput gene expression study. J Neuroimmunol 2010;221:87-94.
28. Jolivel V, Luessi F, Masri J, et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 2013;136:1048-66.
29. Wegner C, Stadelmann C, Pfortner R, et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 2010;227:133-43.
30. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-24.